NCT00733031 - Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD6918 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions

Cancer,Solid TumorsAdvanced Solid Malignancies

Interventions

DRUG

AZD6918

liquid suspension, daily, oral dose

DRUG

gemcitabine

intravenous, doses are on an intermittent schedule

DRUG

pemetrexed

intravenous, dose administered every 21-days

Trial Locations (2)

Research Site, Aurora

Research Site, Nashville